Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients
- 13 Downloads
Moyamoya angiopathy (MMA) is a rare vasopathy, especially among European Caucasians. Data about demographics, clinical presentation, comorbid conditions, radiological findings as well as laboratory and cerebral spinal fluid (CSF) data are sparse.
Patients with MMA treated in the Alfried Krupp Hospital, Essen, Germany, between 2010 and 2017 with focus on demographic, clinical, radiological and laboratory as well as CSF data were evaluated retrospectively. Patients with non-Caucasian family background were excluded from this study.
Altogether 200 European Caucasian patients with MMA were identified. There was a female predominance of 3.2:1. The mean age at first presentation was 32.9 years and the mean age of diagnosis was 36.0 years. Eleven of 194 index patients (5.7%) showed a familial presentation. In 11.6% posterior cerebral artery was additionally involved, in 4% additionally cerebral aneurysm and in 2.5% dysgenesis of corpus callosum was found. Most patients suffered from transient ischemic attacks (71.5%) and stroke (82%). Cerebral hemorrhage was found in 9.5%. Livedo racemosa was an associated symptom in 12.8% of patients and thyroid diseases were found in 23.8%.
Compared with Asian data, cerebral hemorrhages are infrequent and female predominance is accentuated among European Caucasians. Some former unknown rare features like associated livedo racemosa, dysgenesis of corpus callosum and associated syncope have been discovered systematically for the first time in this huge European Caucasian cohort.
KeywordsMoyamoya angiopathy Europeans Clinical presentation Demographics Moyamoya Caucasians Europe
There was no funding.
Compliance with ethical standards
Conflicts of interest
Markus Kraemer received research grants from Novartis and Merck Serono and travel/accommodation/meeting expenses or lecture honoraria from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Teva and Shire Germany. Jan Claudius Schwitalla has no conflict of interest. Frank Diesner has no conflict of interest. Hans-Peter Hartung received, with approval of the Rector of Heinrich-Heine-University and the CEO of University of Düsseldorf Hospital honoraria for consulting, serving on steering committees and speaking from Biogen, CSL Behring, Geneuro, Genzyme, LFB, Medimmune, Merck, Novartis, Octapharma, Opexa, Receptos/Celgene, Roche, Sanofi, and Teva. Orhan Aktas received, with approval of the Rector of Heinrich-Heine-University, grants from the German Research Foundation (DFG), the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS; for NEMOS NationNMO-PAT FKZ 01GI1602B), the Eugène Devic European Network (EU-FP7), honoraria and travel/accommodation/meeting expenses from Almirall, Bayer, Biogen, Medimmune, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. Peter Berlit has no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.Health Labour Sciences Research Grant for Research on Measures for Infractable D (2012) Treatment of spontaneous occlusion of the circle of W. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 52(5):245–266CrossRefGoogle Scholar
- 4.Guey S, Kraemer M, Herve D, Ludwig T, Kossorotoff M, Bergametti F, Schwitalla JC, Choi S, Broseus L, Callebaut I, Genin E, Tournier-Lasserve E, Consortium F (2017) Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians. Eur J Hum Genet 25(8):995–1003. https://doi.org/10.1038/ejhg.2017.92 CrossRefGoogle Scholar
- 8.Kraemer M, Karakaya R, Matsushige T, Graf J, Albrecht P, Hartung HP, Berlit P, Laumer R, Diesner F (2018) Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures. J Neurol. https://doi.org/10.1007/s00415-018-9031-4 Google Scholar
- 9.Kraemer M, Sassen J, Karakaya R, Schwitalla JC, Graf J, Albrecht P, Hartung HP, Diehl RR, Berlit P, Laumer R, Diesner F (2018) Moyamoya angiopathy: early postoperative course within 3 months after STA-MCA-bypass surgery in Europe-a retrospective analysis of 64 procedures. J Neurol. https://doi.org/10.1007/s00415-018-8997-2 Google Scholar
- 11.Acker G, Goerdes S, Schmiedek P, Czabanka M, Vajkoczy P (2016) Characterization of clinical and radiological features of quasi-Moyamoya disease among European Caucasians including surgical treatment and outcome. Cerebrovasc Dis 42(5–6):464–475. https://doi.org/10.1159/000448812 CrossRefGoogle Scholar
- 13.Khan N, Schuknecht B, Boltshauser E, Capone A, Buck A, Imhof HG, Yonekawa Y (2003) Moyamoya disease and Moyamoya syndrome: experience in Europe; choice of revascularisation procedures. Acta Neurochir (Wien) 145(12):1061–1071. https://doi.org/10.1007/s00701-003-0148-5 (discussion 1071) CrossRefGoogle Scholar
- 15.Uchino K, Johnston SC, Becker KJ, Tirschwell DL (2005) Moyamoya disease in Washington state and California. Neurology 65(6):956–958. https://doi.org/10.1212/01.wnl.0000176066.33797.82 CrossRefGoogle Scholar
- 19.Grangeon L, Guey S, Schwitalla JC, Bergametti F, Arnould M, Corpechot M, Hadjadj J, Riant F, Aloui C, Drunat S, Vidaud D, Tournier-Lasserve E, Kraemer M (2019) Clinical and molecular features of 5 European multigenerational families with Moyamoya angiopathy. Stroke. https://doi.org/10.1161/STROKEAHA.118.023972 Google Scholar
- 21.Ohkura A, Negoto T, Aoki T, Noguchi K, Okamoto Y, Komatani H, Kawano T, Mukasa A, Morioka M (2018) Stenotic changes of the posterior cerebral artery are a major contributing factor for cerebral infarction in moyamoya disease. Surg Neurol Int 9:105. https://doi.org/10.4103/sni.sni_18_18 CrossRefGoogle Scholar
- 24.Santoro C, Giugliano T, Kraemer M, Torella A, Schwitalla JC, Cirillo M, Melis D, Berlit P, Nigro V, Perrotta S, Piluso G (2018) Whole exome sequencing identifies MRVI1 as a susceptibility gene for moyamoya syndrome in neurofibromatosis type 1. PLoS One 13(7):e0200446. https://doi.org/10.1371/journal.pone.0200446 CrossRefGoogle Scholar
- 25.Milewicz DM, Ostergaard JR, Ala-Kokko LM, Khan N, Grange DK, Mendoza-Londono R, Bradley TJ, Olney AH, Ades L, Maher JF, Guo D, Buja LM, Kim D, Hyland JC, Regalado ES (2010) De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A 152A(10):2437–2443. https://doi.org/10.1002/ajmg.a.33657 CrossRefGoogle Scholar
- 26.Hess CP, Fullerton HJ, Metry DW, Drolet BA, Siegel DH, Auguste KI, Gupta N, Haggstrom AN, Dowd CF, Frieden IJ, Barkovich AJ (2010) Cervical and intracranial arterial anomalies in 70 patients with PHACE syndrome. AJNR Am J Neuroradiol 31(10):1980–1986. https://doi.org/10.3174/ajnr.A2206 CrossRefGoogle Scholar
- 32.Herve D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S, Bergametti F, Essongue A, Berrou E, Krivosic V, Sainte-Rose C, Houdart E, Adam F, Billiemaz K, Lebret M, Roman S, Passemard S, Boulday G, Delaforge A, Guey S, Dray X, Chabriat H, Brouckaert P, Bryckaert M, Tournier-Lasserve E (2014) Loss of alpha1beta1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet 94(3):385–394. https://doi.org/10.1016/j.ajhg.2014.01.018 CrossRefGoogle Scholar
- 34.Lanterna LA, Galliani S, Zangari R, Conti L, Brembilla C, Gritti P, Colleoni ML, Bernucci C (2018) Thyroid autoantibodies and the clinical presentation of Moyamoya disease: a prospective study. J Stroke Cerebrovasc Dis 27(5):1194–1199. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.11.037 CrossRefGoogle Scholar
- 35.Herve D, Kossorotoff M, Bresson D, Blauwblomme T, Carneiro M, Touze E, Proust F, Desguerre I, Alamowitch S, Bleton JP, Borsali A, Brissaud E, Brunelle F, Calviere L, Chevignard M, Geffroy-Greco G, Faesch S, Habert MO, De Larocque H, Meyer P, Reyes S, Thines L, Tournier-Lasserve E, Chabriat H (2018) French clinical practice guidelines for Moyamoya angiopathy. Rev Neurol (Paris) 174(5):292–303. https://doi.org/10.1016/j.neurol.2017.12.002 CrossRefGoogle Scholar